Trevi Therapeutics, Inc. (TRVI)
TRVI moved a median of -0.59% 30 minutes after news, and 0.00% by the close. How TRVI actually reacts to news — the realized, point-in-time move the market made, measured across 256 labeled events over the last three years with zero look-ahead.
TRVI’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 42% | 255 |
| 30-min | -0.59% | 39% | 256 |
| 60-min | -0.51% | 40% | 256 |
| to close | 0.00% | 50% | 254 |
| Middle 50% of TRVI reactions | -1.88% to +1.12% |
|---|---|
| Median reaction (30-min) | -0.59% |
| Measured reactions | 256 |
Half of all Trevi Therapeutics, Inc. news events land between -1.88% and +1.12% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How TRVI reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Coverage initiations | 29 | -0.71% | 41% | +1.94% |
| Rating reiterations | 101 | -0.66% | 36% | -1.89% |
| Price-target raises | 10 | -2.66% | 40% | -8.03% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 3 further classes were observed with fewer than 10 measured events and are not published. See how TRVI ranks against every other measured name →
That’s how TRVI usually reacts — get an email when it moves on news →Email me when TRVI moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to TRVI's baseline. Nothing else.
Recent TRVI events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Trevi Therapeutics Announces Oral Presentation Accepted at the CHEST 2026 Annual Meeting | Press release | GlobeNewswire | +2.55% | -4.43% | |
| Trevi Therapeutics to Participate in Upcoming September Conferences | Press release | GlobeNewswire | -2.46% | -0.18% | |
| Trevi Therapeutics Announces Upcoming Presentations at the European Respiratory Society (ERS) Congress 2026 | Press release | GlobeNewswire | -0.84% | +0.17% | |
| Form 10-Q Trevi Therapeutics, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -3.69% | -3.89% | |
| Form 8-K Trevi Therapeutics, Inc. For: Aug 06 | SEC filing · Form 8-K | SEC EDGAR | -3.69% | -3.89% | |
| Form S-8 Trevi Therapeutics, Inc. | SEC filing · Form S-8 | SEC EDGAR | -3.69% | -3.89% | |
| Trevi Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates | Press release | GlobeNewswire | -3.69% | -3.89% | |
| Trevi Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026 | Press release | GlobeNewswire | -2.22% | -1.30% | |
| Trevi Therapeutics to Participate in Upcoming August Conferences | Press release | GlobeNewswire | +0.33% | +0.88% | |
| Trevi Therapeutics Announces Upcoming June and July Event Schedule | Press release | GlobeNewswire | -0.29% | +5.14% | |
| Form 8-K Trevi Therapeutics, Inc. For: Jun 03 | SEC filing · Form 8-K | SEC EDGAR | +0.14% | -3.82% | |
| Form 10-Q Trevi Therapeutics, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.14% | +0.85% | |
| Form 8-K Trevi Therapeutics, Inc. For: May 05 | SEC filing · Form 8-K | SEC EDGAR | +0.14% | +0.85% | |
| Trevi Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates | Press release | GlobeNewswire | +0.14% | +0.85% | |
| Trevi Therapeutics Announces Oral Presentation and Multiple Posters Accepted at the American Thoracic Society (ATS) 2026 International Conference | Press release | GlobeNewswire | +0.65% | +0.07% | |
| Trevi Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 5, 2026 | Press release | GlobeNewswire | +0.33% | +1.10% | |
| Trevi Therapeutics to Participate in Upcoming May Events | Press release | GlobeNewswire | +0.41% | +2.93% | |
| Form ARS Trevi Therapeutics, Inc. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.65% | +0.54% | |
| Form DEF 14A Trevi Therapeutics, Inc. For: Apr 21 | SEC filing · Form DEF | SEC EDGAR | +0.65% | +0.54% | |
| Form DEFA14A Trevi Therapeutics, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | +0.65% | +0.54% | |
| Trevi Therapeutics Announces Closing of $173 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares | Press release | GlobeNewswire | -0.20% | -5.10% | |
| Form 8-K Trevi Therapeutics, Inc. For: Apr 16 | SEC filing · Form 8-K | SEC EDGAR | -1.80% | +5.54% | |
| Trevi Therapeutics Announces Pricing of $150 Million Underwritten Offering of Common Stock | Press release | GlobeNewswire | -1.80% | +5.54% | |
| Trevi Therapeutics Announces Proposed Public Offering of Common Stock | Press release | GlobeNewswire | -1.80% | +5.54% | |
| Form PRE 14A Trevi Therapeutics, Inc. For: Apr 10 | SEC filing · Form PRE | SEC EDGAR | -0.23% | +1.06% | |
| Trevi Therapeutics to Participate in Upcoming Events | Press release | GlobeNewswire | +1.85% | -4.77% | |
| Form 10-K Trevi Therapeutics, Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -6.49% | -9.87% | |
| Form 8-K Trevi Therapeutics, Inc. For: Mar 17 | SEC filing · Form 8-K | SEC EDGAR | -6.49% | -9.87% | |
| Trevi Therapeutics Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Updates | Press release | GlobeNewswire | -6.49% | -9.87% | |
| Trevi Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results and Provide Business Updates on March 17, 2026 | Press release | GlobeNewswire | -0.09% | +1.53% | |
| Form 8-K Trevi Therapeutics, Inc. For: Mar 09 | SEC filing · Form 8-K | SEC EDGAR | +2.31% | +0.51% | |
| Trevi Therapeutics Announces Completion of End-of-Phase 2 Meeting with the FDA, Gaining Alignment for Its Development Program for Idiopathic Pulmonary Fibrosis-Related Chronic Cough | Press release | GlobeNewswire | +2.49% | -9.02% | |
| Trevi Therapeutics to Participate in Upcoming March Conferences | Press release | GlobeNewswire | +4.00% | +6.98% | |
| Trevi Therapeutics to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference | Press release | GlobeNewswire | +0.86% | -2.69% | |
| Trevi Therapeutics Announces Publication of Data from the Phase 2b IPF Chronic Cough Trial of nalbuphine ER in the Journal of the American Medical Association (JAMA) | Press release | PR Newswire | +0.27% | +1.77% | |
| Trevi Therapeutics Provides Strategic Updates Ahead of Annual LifeSci Partners Corporate Access Event Held During the J.P. Morgan Healthcare Conference | Press release | PR Newswire | +0.00% | -4.19% | |
| Form 8-K Trevi Therapeutics, Inc. For: Dec 01 | SEC filing · Form 8-K | SEC EDGAR | +0.11% | -0.59% | |
| Trevi Therapeutics Announces Appointment of David Hastings as Chief Financial Officer | Press release | PR Newswire | +0.00% | -0.07% | |
| Trevi Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on November 13, 2025 | Press release | PR Newswire | +0.09% | +0.09% | |
| Trevi Therapeutics to Participate in Stifel 2025 Healthcare Conference | Press release | PR Newswire | +0.48% | +3.92% | |
| Trevi Therapeutics Announces Oral Presentation and Abstracts at CHEST 2025 Annual Meeting | Press release | PR Newswire | -0.77% | +0.72% | |
| Trevi Therapeutics Announces Two Posters from the Phase 2a RIVER Trial Data Will be Featured at the European Respiratory Society (ERS) Congress 2025 | Press release | PR Newswire | +1.37% | +6.35% | |
| Trevi Therapeutics to Participate in Upcoming September Conferences | Press release | PR Newswire | -3.13% | -11.64% | |
| Form 8-K Trevi Therapeutics, Inc. For: Aug 14 | SEC filing · Form 8-K | SEC EDGAR | +0.13% | -0.80% | |
| Form 10-Q Trevi Therapeutics, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -0.69% | +2.91% | |
| Form 8-K Trevi Therapeutics, Inc. For: Aug 07 | SEC filing · Form 8-K | SEC EDGAR | -0.69% | +2.91% | |
| Form S-8 Trevi Therapeutics, Inc. | SEC filing · Form S-8 | SEC EDGAR | -0.69% | +2.91% | |
| Trevi Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates | Press release | PR Newswire | -0.69% | +2.91% | |
| Trevi Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 7, 2025 | Press release | PR Newswire | +0.54% | -1.08% | |
| Trevi Therapeutics to Participate in Upcoming August Conferences | Press release | PR Newswire | -0.72% | — |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the TRVI section they belong to.
Where else TRVI is measured.
TRVI earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Trevi Therapeutics, Inc.'s median reaction calculated?
Every labeled TRVI news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 256 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 39% of TRVI's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does TRVI's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.